Ketoconazole therapy for hormonally refractive metastatic prostate cancer.
Twenty-two patients who had progressive metastatic prostatic carcinoma (Stage D2) despite androgen-deprivation therapy (bilateral orchiectomy, 10 cases; bilateral orchiectomy followed by diethylstilbestrol, 7 cases; diethylstilbestrol, 3 cases; combined megestrol acetate and low-dose estrogen, 2 cases) were treated with ketoconazole. Of 19 evaluable patients, 2 (11%) achieved a partial response (for 6 and 8 months) and 7 others (37%) achieved stabilization of disease (for periods of 3-8 months). Of 16 patients in whom pain was a prominent clinical feature, 13 (81%) noted improvement in pain for periods of one to eight months (median 3 months). We conclude that ketoconazole is a useful addition to our current armory for management of patients with metastatic prostatic cancer resistant to prior hormonal therapy.
Johnson
D E
DE
Department of Urology, University of Texas, M.D. Anderson Hospital and Tumor Institute, Houston.
Babaian
R J
RJ
von Eschenbach
A C
AC
Wishnow
K I
KI
Tenney
D
D
D000368:Aged; D000369:Aged, 80 and over; D000728:Androgens; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary* / Q000628:therapy; D002277:Carcinoma / Q000188:drug therapy / Q000556:secondary* / Q000628:therapy; D003131:Combined Modality Therapy; D004054:Diethylstilbestrol / Q000627:therapeutic use; D006801:Humans; D007654:Ketoconazole / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009376:Neoplasms, Hormone-Dependent / Q000628:therapy*; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000628:therapy
D000728:Androgens; D004054:Diethylstilbestrol; D007654:Ketoconazole